Alexion Pharmaceuticals (ALXN) Stock Rating Reaffirmed by Leerink Swann
Alexion Pharmaceuticals (NASDAQ:ALXN)‘s stock had its “buy” rating reissued by equities research analysts at Leerink Swann in a report issued on Wednesday. They presently have a $169.00 target price on the biopharmaceutical company’s stock. Leerink Swann’s target price indicates a potential upside of 54.45% from the stock’s previous close.
Other equities research analysts also recently issued research reports about the company. Royal Bank Of Canada lifted their target price on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price for the company in a report on Tuesday, October 31st. Stifel Nicolaus dropped their target price on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a report on Tuesday, October 24th. Deutsche Bank reissued a “buy” rating and set a $158.00 target price (up previously from $153.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Finally, SunTrust Banks reissued a “buy” rating and set a $180.00 target price (up previously from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average target price of $154.49.
Alexion Pharmaceuticals (NASDAQ ALXN) traded up $0.52 on Wednesday, hitting $109.42. The stock had a trading volume of 1,935,700 shares, compared to its average volume of 2,286,650. Alexion Pharmaceuticals has a 12 month low of $96.18 and a 12 month high of $149.34. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $24,329.31, a P/E ratio of 22.27, a P/E/G ratio of 1.18 and a beta of 1.18.
A number of institutional investors have recently added to or reduced their stakes in ALXN. Fiduciary Trust Co. bought a new position in Alexion Pharmaceuticals in the second quarter valued at about $111,000. Valeo Financial Advisors LLC bought a new position in Alexion Pharmaceuticals in the third quarter valued at about $147,000. Penserra Capital Management LLC grew its position in Alexion Pharmaceuticals by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 144 shares during the last quarter. Dupont Capital Management Corp bought a new position in Alexion Pharmaceuticals in the third quarter valued at about $156,000. Finally, Acadian Asset Management LLC bought a new position in Alexion Pharmaceuticals in the second quarter valued at about $160,000. Hedge funds and other institutional investors own 94.16% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.